Neos Therapeutics (NEOS) Posts Wider-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Neos Therapeutics (NEOS) Posts Wider-than-Expected Q3 Loss
November 10, 2015 5:59 PM EST
Company Announces Financial Results for the Third Quarter Ended September 30, 2015
Conference call scheduled for November 11, 2015 at 8:30am ET
DALLAS and FORT WORTH, Texas, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company with a latestage pipeline of innovative extended-release (XR) product candidates for the treatment of attention deficit hyperactivity disorder (ADHD), today announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Cotempla XR-ODT (Methylphenidate... More
November 10, 2015 5:59 PM EST
Company Announces Financial Results for the Third Quarter Ended September 30, 2015
Conference call scheduled for November 11, 2015 at 8:30am ET
DALLAS and FORT WORTH, Texas, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company with a latestage pipeline of innovative extended-release (XR) product candidates for the treatment of attention deficit hyperactivity disorder (ADHD), today announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Cotempla XR-ODT (Methylphenidate... More
